StockNews.AI
CNTX
StockNews.AI
78 days

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

1. Context Therapeutics presented a trial for CTIM-76 at ASCO 2025. 2. CTIM-76 targets CLDN6-positive solid tumors in advanced cancer patients. 3. First patient dosed in January 2025; data release expected in 2026. 4. Trial involves 70 patients assessing safety and efficacy. 5. CTIM-76 shows potential for scalable production with low immunogenicity risk.

7m saved
Insight
Article

FAQ

Why Bullish?

Presentation at a significant industry event like ASCO could generate investor interest, similar to historical examples where clinical data announcements led to stock price increases.

How important is it?

The announcement provides crucial information that may lead to future advancements and investor confidence.

Why Long Term?

Initial data release in 2026 can impact the stock long-term, affecting future funding and partnerships.

Related Companies

AVEOMDGL
June 02, 2025 07:30 ET  | Source: Context Therapeutics Inc. Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and testicular cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2025 in Chicago, IL. The Phase 1 clinical trial is an open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 in subjects with CLDN6-positive advanced or metastatic ovarian, endometrial, and testicular cancers. The dose escalation and dose expansion portions of the trial are expected to evaluate safety, tolerability, and pharmacokinetics as well as anti-tumor activity by overall response rate, duration of response, and disease control rate. The study is expected to enroll up to 70 patients. CTIM-76 Highlights and Near-Term Milestones Dosed first patient in January 2025 and currently dosing cohort 37 active trial sites in the United StatesExpect to share initial data in the first half of 2026 Poster Presentation Details: Title: A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumorsAbstract Number: TPS2685Poster Session: Developmental Therapeutics—ImmunotherapyDate and Time: Monday June 2, 2025, 1:30 PM CDTLocation: Hall APoster Board Number: 323b A copy of the presentation materials will be made available on the “Publications and Posters” section of the Company’s website at https://www.contexttherapeutics.com. About CTIM-76CTIM-76 is a CLDN6 x CD3 T cell engaging bispecific antibody. CLDN6 is enriched in a wide range of solid tumors, including ovarian, endometrial, lung, gastric, and testicular. Preclinical research suggests the potential for convenient dosing with low immunogenicity risk and scalable manufacturing to address the significant number of patients who are potentially eligible for CTIM-76 therapy. More information about the CTIM-76 clinical trial (NCT06515613) can be found on https://clinicaltrials.gov/. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 TCE, CT-95, a Mesothelin x CD3 TCE, and CT-202, a Nectin-4 x CD3 TCE. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn. Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as “may,” “will,” “expect,” “anticipate,” “look forward,” “plan,” “intend,” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the ability of the Company, its employees and certain ASCO presenters to participate in and present at conferences, (ii) our expectation to share initial clinical data in the first half of 2026 for CTIM-76, (iii) the potential benefits, characteristics, safety and side effect profile of our product candidates, (iv) our expectation regarding what the trial is intended to evaluate and the number of patients to be enrolled, (v) the likelihood data will support future development, and (vi) the likelihood of obtaining regulatory approval for our product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise. Investor Relations Contact:Jennifer Minai-AzaryChief Financial OfficerContext Therapeutics Inc.IR@contexttherapeutics.com

Related News